Alcobra (ADHD) Announces New Biomarker Finding In A Follow-Up Fragile X Animal Study For MG01CI
1/27/2014 8:53:54 AM
TEL AVIV, Israel, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine Extended-Release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today positive results from a new study in Fmr1 knock-out mice, a validated animal model of Fragile X Syndrome. The study revealed that normalization of certain over-activated biological markers was evident in the blood and brains of test mice following treatment with Metadoxine. This finding raises the possibility of using this effect as a screening tool in future clinical investigations for identifying patients who are more likely to respond to treatment and monitoring their response over time.
Help employers find you! Check out all the jobs and post your resume.
comments powered by